Gordon Keller
A world-renowned stem cell scientist, Dr. Keller became Director of the McEwen Stem Cell Institute (formerly the McEwen Centre for Regenerative Medicine) at the University Health Network in Toronto Canada in 2007. Dr. Keller is the premier researcher, worldwide, in the application of developmental biology-guided principles to the differentiation of pluripotent stem cells (PSCs) into therapeutically relevant cells, such as cardiomyocytes, hematopoietic cells and liver cells.
Dr. Gordon Keller earned his PhD in Immunology at the University of Alberta in 1979 and completed a Post Doctoral Fellowship at the Ontario Cancer Institute in Toronto in 1983. Following post doctoral studies, he became a Member of the Basel Institute for Immunology in Switzerland where he worked for five years, then moved to Vienna, Austria where he accepted a post of Visiting Scientist at the Research Institute of Molecular Pathology. In 1990, Keller moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado and from 1999–2006 as a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York. In 2005, he was appointed the Director of the Black Family Stem Cell Institute within the Mt. Sinai School of Medicine. In January 2007, Keller returned to Canada to accept the position of Director of the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto.
In addition to his position at the McEwen Stem Cell Institute, Dr. Keller is a Senior Scientist at The Princess Margaret Cancer Centre, a Professor at the University of Toronto, Department of Medical Biophysics as well as a founding Board member of the International Society of Stem Cell Research. In December 2016, Keller was named scientific co-founder of BlueRock Therapeutics, a next-generation regenerative medicine company.
Dr. Gordon Keller earned his PhD in Immunology at the University of Alberta in 1979 and completed a Post Doctoral Fellowship at the Ontario Cancer Institute in Toronto in 1983. Following post doctoral studies, he became a Member of the Basel Institute for Immunology in Switzerland where he worked for five years, then moved to Vienna, Austria where he accepted a post of Visiting Scientist at the Research Institute of Molecular Pathology. In 1990, Keller moved to the United States, working initially at the National Jewish Centre for Immunology and Respiratory Medicine in Denver Colorado and from 1999–2006 as a Professor in the Department of Gene and Cell Medicine at the Mt. Sinai School of Medicine in New York. In 2005, he was appointed the Director of the Black Family Stem Cell Institute within the Mt. Sinai School of Medicine. In January 2007, Keller returned to Canada to accept the position of Director of the McEwen Centre for Regenerative Medicine at the University Health Network in Toronto.
In addition to his position at the McEwen Stem Cell Institute, Dr. Keller is a Senior Scientist at The Princess Margaret Cancer Centre, a Professor at the University of Toronto, Department of Medical Biophysics as well as a founding Board member of the International Society of Stem Cell Research. In December 2016, Keller was named scientific co-founder of BlueRock Therapeutics, a next-generation regenerative medicine company.